✉news HealthMedicine first seen 8 h ago, last 2 h ago, peak #2
Insilico Medicine unveils AI-designed obesity drug candidate ISM1354
Original: Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease
Insilico Medicine has nominated ISM1354, a GIPR antagonist designed using its artificial intelligence drug discovery platform, as a preclinical candidate for obesity and related metabolic diseases. The company says the molecule was generated and optimised end-to-end with generative AI tools. It adds to a growing slate of AI-discovered drugs moving toward clinical development, as pharmaceutical firms race to apply machine learning to the booming obesity treatment market.
Why now: AI-designed drugs for obesity are attracting attention amid intense industry competition in the weight-loss treatment space.
Rank over time, top of the chart is #1. 5 snapshots from 8 h ago to 2 h ago.
Evidence
- Insilico Medicine nominates AI-designed GIPR antagonist ISM1354 for obesity and metabolic disease · Drug Target Review
API: https://socialmediatrends-api.osmike.com/v1/trends/715586